Alla Verlinsky

Medicine · Health Sciences

10h-index1.3kcitations35works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(15), HER2/EGFR in Cancer Research(10), Glycosylation and Glycoproteins Research(6), Colorectal Cancer Treatments and Studies(4), Cancer Cells and Metastasis(3)

Publications35 total

Supplementary Data from The Discovery and Preclinical Development of ASG-5ME, an Antibody–Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer
2023Open Access
Data from AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody–Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML
2023Open Access
Supplementary Figures S1-S4 and Supplementary Methods from AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody–Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML
2023Open Access
Data from Development of ASG-15ME, a Novel Antibody–Drug Conjugate Targeting <i>SLITRK6</i>, a New Urothelial Cancer Biomarker
2023Open Access
Supplementary Materials and Methods: Generation of IHC Reagent M15-68(2)22 from Development of ASG-15ME, a Novel Antibody–Drug Conjugate Targeting <i>SLITRK6</i>, a New Urothelial Cancer Biomarker
2023Open Access
Data from Development of ASG-15ME, a Novel Antibody–Drug Conjugate Targeting <i>SLITRK6</i>, a New Urothelial Cancer Biomarker
2023Open Access
Supplementary Materials and Methods: Generation of IHC Reagent M15-68(2)22 from Development of ASG-15ME, a Novel Antibody–Drug Conjugate Targeting <i>SLITRK6</i>, a New Urothelial Cancer Biomarker
2023Open Access
Supplementary Figures S1-S4 and Supplementary Methods from AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody–Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML
2023Open Access
Data from AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody–Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML
2023Open Access
Supplementary Data from The Discovery and Preclinical Development of ASG-5ME, an Antibody–Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer
2023Open Access
Data from The Discovery and Preclinical Development of ASG-5ME, an Antibody–Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer
2023Open Access
Data from The Discovery and Preclinical Development of ASG-5ME, an Antibody–Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer
2023Open Access
Supplementary Figures 1 and 2 and Supplementary Table 1 from Enfortumab Vedotin Antibody–Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models
2023Open Access
Supplementary Figures 1 and 2 and Supplementary Table 1 from Enfortumab Vedotin Antibody–Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models
2023Open Access
Data from Enfortumab Vedotin Antibody–Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models
2023Open Access
Data from Enfortumab Vedotin Antibody–Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models
2023Open Access
Abstract 1057: Combination of the KRASG12C inhibitor sotorasib with targeted agents improves anti-tumor efficacy in <i>KRAS p.G12C</i> cancer models
Cancer Research·2021
Abstract 6218: Discovery and preclinical evaluation of AMG 397, a potent, selective and orally bioavailable MCL1 inhibitor
Cancer Research·2020· 42 cited
Silicone Oil Particles in Prefilled Syringes With Human Monoclonal Antibody, Representative of Real-World Drug Products, Did Not Increase Immunogenicity in In Vivo and In Vitro Model Systems
Journal of Pharmaceutical Sciences·2019· 30 cited
The Discovery and Preclinical Development of ASG-5ME, an Antibody–Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer
Molecular Cancer Therapeutics·2016· 42 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

David R. Stover(31), Pia M. Challita-Eid(29), Zili An(29), Ingrid B.J. Joseph(27), Héctor Aviña(24), Kendall Morrison(24), Daniel S. Pereira(23), Fernando Doñate(22), Linnette Capo(21), Claudia Guevara(18), Arthur Raitano(15), Monica Leavitt(13), Sher Karki(12), Joseph D. Abad(12), Karen Morrison(12), Faisal Malik(12), Peng Yang(12), Wendy Liu(11), Dawn Ratay Lortie(11), Karen Morrison(10)